60,053 Shares in Illumina, Inc. (NASDAQ:ILMN) Bought by Massar Capital Management LP

Massar Capital Management LP purchased a new stake in Illumina, Inc. (NASDAQ:ILMN - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 60,053 shares of the life sciences company's stock, valued at approximately $8,025,000. Illumina makes up 9.1% of Massar Capital Management LP's investment portfolio, making the stock its 2nd biggest holding.

Several other large investors have also modified their holdings of the business. Versant Capital Management Inc raised its stake in shares of Illumina by 153.7% during the 4th quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company's stock worth $32,000 after acquiring an additional 146 shares in the last quarter. Golden State Wealth Management LLC bought a new position in shares of Illumina during the 4th quarter worth approximately $32,000. Assetmark Inc. raised its stake in shares of Illumina by 954.8% during the 4th quarter. Assetmark Inc. now owns 327 shares of the life sciences company's stock worth $44,000 after acquiring an additional 296 shares in the last quarter. Bank Julius Baer & Co. Ltd Zurich bought a new position in shares of Illumina during the 4th quarter worth approximately $45,000. Finally, Lee Danner & Bass Inc. bought a new position in shares of Illumina during the 4th quarter worth approximately $48,000. Institutional investors own 89.42% of the company's stock.

Analysts Set New Price Targets

Several research analysts recently commented on ILMN shares. Guggenheim reduced their price objective on shares of Illumina from $170.00 to $150.00 and set a "buy" rating for the company in a research note on Friday, February 7th. Stephens restated an "overweight" rating and set a $156.00 price target on shares of Illumina in a research note on Tuesday, March 11th. Robert W. Baird cut their price target on shares of Illumina from $127.00 to $90.00 and set a "neutral" rating on the stock in a research note on Wednesday, March 5th. Royal Bank of Canada cut their price target on shares of Illumina from $128.00 to $112.00 and set an "outperform" rating on the stock in a research note on Tuesday, April 8th. Finally, Hsbc Global Res downgraded shares of Illumina from a "strong-buy" rating to a "hold" rating in a report on Friday, February 28th. One equities research analyst has rated the stock with a sell rating, ten have issued a hold rating, ten have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Illumina presently has a consensus rating of "Moderate Buy" and a consensus price target of $138.70.

Illumina Trading Down 0.3 %

ILMN traded down $0.26 during trading hours on Friday, reaching $77.35. The company's stock had a trading volume of 1,424,483 shares, compared to its average volume of 2,286,599. Illumina, Inc. has a fifty-two week low of $68.70 and a fifty-two week high of $156.66. The stock has a market cap of $12.24 billion, a PE ratio of -10.07, a P/E/G ratio of 1.60 and a beta of 1.38. The business's 50-day moving average is $82.02 and its 200-day moving average is $117.87. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.77 and a quick ratio of 1.42.

Illumina (NASDAQ:ILMN - Get Free Report) last released its quarterly earnings results on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing analysts' consensus estimates of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. As a group, equities research analysts predict that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.